Biden administration delays plans to ban menthol cigarettes

Biden administration delays plans to ban menthol cigarettes


U.S. President Joe Biden speaks after signing into law a bill providing billions of dollars of new aid to Ukraine for its war with Russia, at the White House in Washington, U.S., April 24, 2024. 

Elizabeth Frantz | Reuters

The Biden Administration has delayed plans to ban menthol cigarettes, a proposal announced by the Food and Drug Administration years ago.

“There are still more conversations to have, and that will take significantly more time,” Department of Health and Human Services Secretary Xavier Becerra said in a statement Friday.

The FDA announced its plans to ban menthol tobacco cigarettes in 2021, followed by its proposed rules for the ban in 2022. The move was aimed to improve the health of those most likely to smoke them, including kids and Black Americans.

According to the FDA, nearly 85% of Black smokers use menthol cigarettes, compared to just 30% of white smokers. Black men have the highest lung cancer death rate in the U.S. and both Black men and women are far less likely to be diagnosed with the disease at an early stage, when it is often more treatable, than white Americans.

The proposed ban — and now the delay — has raised questions about the effect it could have on Black voters months before a contentious presidential election.

The ban has already been delayed at least once, with promises of it being enacted by the end of last year coming and going. At the time, the White House quietly updated its Office of Information and Regulatory Affairs website to reflect that any final ban on menthol wouldn’t happen until at least March.

At the time of the December delay, one official with a national public health group working to remove the products from the market told NBC News they were “deeply concerned” the ban would not take effect before the 2024 election.

“Everything gets harder to do in an election year because people are distracted and bandwidth is stretched,” the official said in December.

Becerra’s statement did not indicate if or when the ban would be enacted by the Biden Administration and provided no further details on conversations around it.

After the delay was announced Friday afternoon, anti-smoking and health advocates began expressing their frustration.

“Two full years after releasing proposed rules backed by extensive scientific evidence — and more than a decade since the FDA began examining menthol cigarettes — the administration has failed to take decisive action to remove these deadly, addictive products from the market,” Nancy Brown, CEO of the American Heart Association, said in a statement. “The administration’s inaction is enabling the tobacco industry to continue aggressively marketing these products and attracting and addicting new users.”



Source

Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More
Making U.S. biotech more competitive with China’s could help rare disease patients, experts say
Health

Making U.S. biotech more competitive with China’s could help rare disease patients, experts say

The growth of China’s biotechnology sector has been staggering. Beijing is pumping money into the industry, backing research efforts and helping launch a new wave of labs and incubators in the country. That’s a problem for the U.S. biotech industry and also affects rare disease patients who are waiting for a cure. Among the experts […]

Read More